Anatara Lifesciences (ASX:ANR), a developer of evidence-based health products, has provided an update on its Anti-Obesity Project.
Preliminary results from pre-clinical studies at the University of Newcastle indicate that Anatara’s candidate compound, "AOC," demonstrated statistically significant activity in managing weight, including reducing rebound weight gain following semaglutide-induced weight loss (P < 0.019) and lowering perigonadal fat deposits (P = 0.024), a key marker of visceral fat.
Completion of the mechanism of action studies has been delayed due to international unavailability of a testing kit, with full data now expected by late January 2026.
The company confirmed that the delay will not incur unexpected costs and noted that the limited MOA assays conducted so far provide guidance for ongoing analyses.
Anatara continues to advance its proof-of-concept studies while pursuing broader business development and strategic opportunities within the healthcare sector, including commercialisation planning for its oral complementary weight management therapy and progress on the GaRP gastrointestinal health project.
At the time of reporting, Anatara Lifesciences' share price was $0.11.